Case Report: Personalized treatment in stage IV breast cancer using the patient-derived organoids
Breast cancer, especially stage IV breast cancer, is highly heterogeneous at morphological and molecular levels. Recently, the role of patient-derived organoids (PDOs) has become increasingly prominent in cancer research and personalized medicine. They are not only used to predict the clinical respo...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-07-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2025.1629690/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850076398848311296 |
|---|---|
| author | Wu Ying Wu Ying Wu Ying Hao Pi Xiaowu He Yuan Sheng |
| author_facet | Wu Ying Wu Ying Wu Ying Hao Pi Xiaowu He Yuan Sheng |
| author_sort | Wu Ying |
| collection | DOAJ |
| description | Breast cancer, especially stage IV breast cancer, is highly heterogeneous at morphological and molecular levels. Recently, the role of patient-derived organoids (PDOs) has become increasingly prominent in cancer research and personalized medicine. They are not only used to predict the clinical responses of patients with multiple cancer types, but also applied to drug development. In this study, we reported a case of stage IV breast cancer who responded well to sacituzumab govitecan that was highly sensitive by the PDO-based drug sensitivity testing, good pathological response was obtained postoperatively. This typical case suggests that PDO-based drug sensitivity testing is conductive to tailoring neoadjuvant chemotherapy options to enhance the feasibility of surgical resection in patients with stage IV breast cancer, thus improving the prognosis. |
| format | Article |
| id | doaj-art-b214d8c79edb40c29ce64efa102e1f44 |
| institution | DOAJ |
| issn | 2234-943X |
| language | English |
| publishDate | 2025-07-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj-art-b214d8c79edb40c29ce64efa102e1f442025-08-20T02:46:02ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2025-07-011510.3389/fonc.2025.16296901629690Case Report: Personalized treatment in stage IV breast cancer using the patient-derived organoidsWu Ying0Wu Ying1Wu Ying2Hao Pi3Xiaowu He4Yuan Sheng5Department of Thyroid and Breast Surgery, Changhai Hospital, Naval Medical University, Shanghai, ChinaDepartment of Breast and Thyroid Surgery, Shanghai Tenth People’s Hospital, Tongji University School of Medicine, Shanghai, ChinaDepartment of General Surgery, The 906th Hospital of the Joint Logistic Support Force of the Chinese People’s Liberation Army, Ningbo, ChinaDepartment of Breast and Thyroid Surgery, Shanghai Tenth People’s Hospital, Tongji University School of Medicine, Shanghai, ChinaDepartment of General Surgery, The 906th Hospital of the Joint Logistic Support Force of the Chinese People’s Liberation Army, Ningbo, ChinaDepartment of Breast and Thyroid Surgery, Shanghai Tenth People’s Hospital, Tongji University School of Medicine, Shanghai, ChinaBreast cancer, especially stage IV breast cancer, is highly heterogeneous at morphological and molecular levels. Recently, the role of patient-derived organoids (PDOs) has become increasingly prominent in cancer research and personalized medicine. They are not only used to predict the clinical responses of patients with multiple cancer types, but also applied to drug development. In this study, we reported a case of stage IV breast cancer who responded well to sacituzumab govitecan that was highly sensitive by the PDO-based drug sensitivity testing, good pathological response was obtained postoperatively. This typical case suggests that PDO-based drug sensitivity testing is conductive to tailoring neoadjuvant chemotherapy options to enhance the feasibility of surgical resection in patients with stage IV breast cancer, thus improving the prognosis.https://www.frontiersin.org/articles/10.3389/fonc.2025.1629690/fullstage IV breast cancerpatient-derived organoidssacituzumab govitecanneoadjuvant therapypathological response |
| spellingShingle | Wu Ying Wu Ying Wu Ying Hao Pi Xiaowu He Yuan Sheng Case Report: Personalized treatment in stage IV breast cancer using the patient-derived organoids Frontiers in Oncology stage IV breast cancer patient-derived organoids sacituzumab govitecan neoadjuvant therapy pathological response |
| title | Case Report: Personalized treatment in stage IV breast cancer using the patient-derived organoids |
| title_full | Case Report: Personalized treatment in stage IV breast cancer using the patient-derived organoids |
| title_fullStr | Case Report: Personalized treatment in stage IV breast cancer using the patient-derived organoids |
| title_full_unstemmed | Case Report: Personalized treatment in stage IV breast cancer using the patient-derived organoids |
| title_short | Case Report: Personalized treatment in stage IV breast cancer using the patient-derived organoids |
| title_sort | case report personalized treatment in stage iv breast cancer using the patient derived organoids |
| topic | stage IV breast cancer patient-derived organoids sacituzumab govitecan neoadjuvant therapy pathological response |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2025.1629690/full |
| work_keys_str_mv | AT wuying casereportpersonalizedtreatmentinstageivbreastcancerusingthepatientderivedorganoids AT wuying casereportpersonalizedtreatmentinstageivbreastcancerusingthepatientderivedorganoids AT wuying casereportpersonalizedtreatmentinstageivbreastcancerusingthepatientderivedorganoids AT haopi casereportpersonalizedtreatmentinstageivbreastcancerusingthepatientderivedorganoids AT xiaowuhe casereportpersonalizedtreatmentinstageivbreastcancerusingthepatientderivedorganoids AT yuansheng casereportpersonalizedtreatmentinstageivbreastcancerusingthepatientderivedorganoids |